23056-33-9

Basic information

• Product Name: 2-Chloro-4-methyl-5-nitropyridine
• Synonyms: 2-CHLORO-4-METHYL-5-NITROPYRIDINE;2-CHLORO-5-NITRO-4-METHYLPYRIDINE;2-CHLORO-5-NITRO-4-PICOLINE;2-CHIORO-4-METHYL-5-NITROPYRIDINE;2-CHLORO-5-NITRO-4-PICOLINE 98+%;2-CHLORO-5-NITRO-4-PICOLINE (2-CHLORO-4-METHYL-5-NITROPYRIDINE);2-chloro-4-methyl-5-nitroppyridine;3-chloro-4-methyl-5-nitropyridine
• CAS NO: 23056-33-9
• Molecular Formula: C₆H₅ClN₂O₂
• Molecular Weight: 172.57
• Product Categories: compounds of pyridine;Pyridine;Pyridines;Pyridine Derivertives;Chloropyridines;Halopyridines;Boronic Acid;C6Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Chlorinated heterocyclic series;pyridine series;Heterocycle-Pyridine series;nitro-compound| alkyl chloride
• Mol File: 23056-33-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 37-39 °C(lit.)
• Boiling Point: 91 °C5 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: Light cream to light brown/Crystalline Powder or Chunks
• Density: 1.5610 (rough estimate)
• Vapor Pressure: 0.0621mmHg at 25°C
• Refractive Index: 1.5870 (estimate)
• Storage Temp.: Room temperature.
• Solubility: soluble in Methanol
• PKA: -3.42±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-4-methyl-5-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4-methyl-5-nitropyridine(23056-33-9)
• EPA Substance Registry System: 2-Chloro-4-methyl-5-nitropyridine(23056-33-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-20/21/22
• Safety Statements: 26-37/39-36/37/39-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 23056-33-9(Hazardous Substances Data)

Usage

Chemical Properties

light cream to light brown crystalline powder

Uses

2-Chloro-4-methyl-5-nitropyridine may be used in chemical synthesis studies.

InChI:InChI=1/C6H5BrClN/c1-4-2-6(8)9-3-5(4)7/h2-3H,1H3

Upstream product

• 21901-41-7 2-hydroxy-4-methyl-5-nitropyridine 
• 21901-41-7 4-methyl-5-nitropyridin-2(1H)-one 
• 695-34-1 2-Amino-4-methylpyridine 
• 21901-40-6 2-amino-5-nitro-4-picoline 

Downstream Products

• 6635-90-1 2-Methoxy-4-methyl-5-nitropyridine 
• 3430-27-1 3-amino-4-methylpyridine 
• 623175-24-6 4-methyl-5-nitro-[2,3]bipyridinyl 
• 25391-79-1 4-methyl-5-nitro-2-pyridinethiol 
• 753920-97-7 C₁₂H₉FN₂O₃ 
• 142078-36-2 2-(2-chloro-3-nitro-4-pyridyl)-N,N-dimethylethenamineine 
• 357262-89-6 1-benzoyl-3-(R)-methyl-4-[(5-chloro-7-methyl-4-azaindol-3-yl)oxoacetyl]piperazine 
• 1417339-72-0 C₂₁H₁₉ClN₄O₃ 
• 357262-86-3 C₂₂H₂₂N₄O₃ 
• 1448447-96-8 butyl 3-(4-methyl-5-nitro-2-oxopyridin-1(2H)-yl)propanoate 
• 920978-99-0 4-methyl-5-nitro-2-phenylpyridine 
• 756839-67-5 5-Fluoro-2-(4-methyl-5-nitro-pyridin-2-yloxy)-benzonitrile 
• 748183-18-8 tert-Butyl [1-(5-amino-4-methylpyridin-2-yl)pyrrolidin-3-yl]methylcarbamate 
• 936368-65-9 2,2-dimethyl-1-[4-(4-methyl-5-nitro-pyridin-2-yl)-piperazin-1-yl]-propan-1-one 

Relevant articles and documents

-

-

Novel pyrazolopyridine derivatives as potential angiogenesis inhibitors: Synthesis, biological evaluation and transcriptome-based mechanistic analysis

Modified purine derivatives exemplified by pyrazolopyrimidines have emerged as highly selective inhibitors of several angiogenic receptor tyrosine kinases. Herein, we designed and synthesized a new series of substituted pyrazolopyridines and explored their ability to influence crucial pro-angiogenic attributes of endothelial cells. Four of the synthesized compounds, possessing analogous substitution pattern, were found able to inhibit at low micromolar concentrations endothelial cell proliferation, migration and differentiation, constitutively or in response to Vascular Endothelial Growth Factor (VEGF) and to attenuate VEGF-induced phosphorylation of VEGF receptor-2 and downstream kinases AKT and ERK1/2. Administration of effective compounds in mice delayed the growth of syngeneic Lewis lung carcinoma transplants and reduced tumor microvessel density, without causing toxicity. Genome-wide microarray and gene ontology analyses of treated endothelial cells revealed derivative 18c as the most efficient modulator of gene expression and mitotic cell cycle/cell divisiong along with ? cholesterol biosynthesis? as the most significantly altered biological processes.

METABOTROPIC GLUTAMATE RECEPTOR MODULATORS

The invention relates to heterocyclic derivatives of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders wherein Y, W, R1, R2 and R3 are as defined in claim 1.